On March 10, 2024, Benjamin Hickey, President of RayzeBio Org., engaged in a transaction involving the common stock of Bristol-Myers Squibb (BMY). Following the transaction, Hickey directly holds 780 shares of the company's common stock, each with a par value of $0.10. Additionally, there are 91 shares held indirectly by Hickey's spouse, bringing the total beneficial ownership to 871 shares. The nature of the indirect ownership is specified as being through the spouse. This transaction reflects changes in the holdings of a key individual within the company, which may be of interest to current and potential investors.

On March 10, 2024, Benjamin Hickey, President of RayzeBio Org., engaged in a transaction involving the common stock of Bristol-Myers Squibb (BMY). Following the transaction, Hickey directly holds 780 shares of the company's common stock, each with a par value of $0.10. Additionally, there are 91 shares held indirectly by Hickey's spouse, bringing the total beneficial ownership to 871 shares. The nature of the indirect ownership is specified as being through the spouse. This transaction reflects changes in the holdings of a key individual within the company, which may be of interest to current and potential investors.